全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Eli Marie Grindedal , Cecilie Heramb , Inga Karsrud ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Identification of BRCA mutations in breast cancer (BC) patients influences treatment and survival and may be of importance for their relatives. Testing is often restricted to women fulfilling high-risk criteria. However, there is limited knowledge of the sensitivity of such a str...
作者:Joaquin Dopazo , Cesim Erten
来源:[J].BMC Systems Biology(IF 2.982), 2017, Vol.11 (1)Springer
摘要:... Several systems biology approaches have been suggested, in particular for the identification of breast cancer (BRCA) related genes. Such approaches usually rely on differential gene expression and/or mutational landscape data. In some cases interaction network data is also in...
作者:A. V. Paradiso , M. Digennaro , M. Patruno ...
来源:[J].BMC Cancer(IF 3.333), 2019, Vol.19 (1), pp.1-6DOAJ
摘要:Abstract Background Delivering widespread BRCA testing to patients with ovarian cancer has been suggested by several scientists, recommended by professional societies and solicited by patients organizations. However, based on the lack of studies clearly demonstrating the cost...
作者:Colombo I , Lheureux S , Oza AM
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2018, Vol.Volume 12, pp.605-617DOAJ
摘要:... Tumors with mutations in BRCA1/2 or other homologous recombination deficiency (HRD) genes are particularly sensitive to PARP inhibitors because of “synthetic lethality”, whereby a therapeutic agent can take advantage of an intrinsic weakness in DNA repair. Rucaparib ha...
作者:B. K. Eccles , E. Copson , T. Maishman ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:Abstract(#br) Background(#br)Mainstreaming genetic medicine, increased media coverage and clinical trials for BRCA mutation carriers are leading oncologists into more patient discussions about BRCA genetic testing. BRCA variants of uncertain significance (VUS) occur in 10–2...
作者:Piera Gargiulo , Matilde Pensabene , Monica Milano ...
来源:[J].BMC Cancer(IF 3.333), 2016, Vol.16 (1)Springer
摘要:... We recorded the following data: baseline characteristics (age, height, weight, body mass index, risk factors, family history), tumor characteristics (side affected, stage, histotype, hormonal and HER2 status, and Ki-67 expression), treatment (type of surgery, chemotherapy, endocrine therapy, and/or radiotherapy), BRCA...
作者:David J. Pulford , Philipp Harter , Anne Floquet ...
来源:[J].BMC Medical Ethics(IF 1.705), 2016, Vol.17 (1)Springer
摘要:...(#br) Methods(#br)An exploratory pharmacogenetic analysis was conducted in the international ovarian cancer phase III trial, AGO-OVAR 16, which found that patients with clinically important germ-line BRCA1/2 mutations had improved progression-free survival prognosis. Mechanism...
作者:Sudhir K. Unni , Marisa B. Schauerhamer , Rishi Deka ...
来源:[J].Journal of Ovarian Research(IF 2.429), 2016, Vol.9 (1)Springer
摘要:Abstract(#br) Background(#br)Breast cancer associated ( BRCA ) genes are critical for DNA repair. Mutations in BRCA1 and BRCA2 ( BRCA m) result in loss of these repair mechanisms and potential carcinogenesis. Germline BRCA m are common in ovarian carcinomas, particularly in plati...
作者:Hua-Sheng Chiu , María Rodríguez Martínez , Mukesh Bansal ...
来源:[J].BMC Genomics(IF 4.397), 2017, Vol.18 (1)Springer
摘要:MicroRNAs (miRNAs) play multiple roles in tumor biology. Interestingly, reports from multiple groups suggest that miRNA targets may be coupled through competitive stoichiometric sequestration. Specifically, computational models predicted and experimental assays confirmed that miR...
作者:Nadine Jalkh , Eliane Chouery , Zahraa Haidar ...
来源:[J].BMC Medical Genomics(IF 3.466), 2017, Vol.10 (1)Springer
摘要:... Mutations in two high susceptibility BRCA1 and BRCA2 genes explain 16–40% of familial BC, while other high, moderate and low susceptibility genes explain up to 20% more of BC families. The Lebanese reported prevalence of BRCA1 and BRCA2 deleterious mutations (5.6% and 1...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×